Premium
Prospective evaluation of XRCC‐1 Arg194Trp polymorphism as bio‐predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin‐based chemoradiation
Author(s) -
Raturi Vijay,
Hojo Hidehiro,
Bhatt M. L. B.,
Suhel Mohammad,
Wu ChenTa,
Bei Yanping,
Nakamura Masaki,
Okumura Masayuki,
Zhang Haiqin,
Parmar Devendra,
Badajena Avinash,
Singh Rahul,
Kumar Saurabh,
Katiyar Tridev,
Gaur Jalaj
Publication year - 2020
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.26083
Subject(s) - medicine , cisplatin , oncology , genotyping , prospective cohort study , clinical endpoint , radiation therapy , chemoradiotherapy , gastroenterology , genotype , chemotherapy , clinical trial , biology , gene , genetics
Background To determine X‐ray repair cross‐complementing 1 gene (XRCC‐1) Arg194Trp polymorphism as bio‐predictor for clinical outcome in advanced laryngeal squamous cell carcinoma undergoing cisplatin‐based chemoradiation (CRT). Methods A total of 150 patients were enrolled in this prospective study. XRCC‐1 Arg194Trp genotyping categorized patients as wild (C/C) and polymorphic (C/T or T/T). The primary endpoint was to assess acute radiation‐induced toxicity (ARIT). Results A significant correlation of skin ( P‐ .04) and oral mucosal ARIT ( P ‐ .01) was noticed in the XRCC‐1 polymorphic variant. A higher treatment response was noted in the polymorphic variant, and it shows a trend toward significance ( P‐ .08). With 33 months of median follow‐up, 2‐year progression‐free survival (PFS) and overall survival (OS) of wild vs polymorphic variant were 34.6% vs 46.9% ( P‐ .066) and 50.6% vs 62.2% ( P ‐ .12). Conclusion XRCC‐1 polymorphic variants have significantly higher oral mucositis and skin ARIT and may have improved trend for treatment response and PFS.